NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.

Rhea-AI Summary

NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.

The company plans to begin dose optimization in Q2 2026 and will present Phase 1 data at ASCO 2026, enabling closer FDA engagement to accelerate development.

Positive

• FDA Fast Track granted for SIM0505 in platinum-resistant ovarian cancer
• Plans to start dose optimization Q2 2026 for ovarian cancer patients
• Phase 1 data scheduled for presentation at ASCO 2026
• SIM0505 targets Cadherin-6 (CDH6) with a proprietary TOPOi payload

Negative

• None.

Argus Apr 7 session

+0.91% close to close Open Argus

Details

News Market Reaction – NXTC

In the Apr 7 session, NXTC gained 0.91%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement grants FDA Fast Track designation to SIM0505 for platinum-resistant ovarian cancer...

Analysis

This announcement grants FDA Fast Track designation to SIM0505 for platinum-resistant ovarian cancer and sets expectations for Phase 1 data at ASCO 2026 and dose optimization in Q2 2026. It builds on a series of ADC-focused clinical milestones that have driven past volatility. Investors may track SIM0505 data quality, enrollment pace, and any follow-on financing or resale activity from the registered 2.52M shares as key risk and dilution markers.

Key Figures

Development stage: Phase 1 Phase 1 data timing: ASCO 2026 Dose optimization start: Q2 2026 +1 more

Development stage

Phase 1

SIM0505 clinical development in platinum-resistant ovarian cancer

Phase 1 data timing

ASCO 2026

Phase 1 data for SIM0505 to be presented at ASCO 2026

Dose optimization start

Q2 2026

Dose optimization in ovarian cancer expected to begin in Q2 2026

Fast Track indication

Platinum-resistant ovarian cancer

FDA Fast Track designation for SIM0505 in PROC

Previous Clinical trial Reports

5 past events · Latest: Nov 17

Same Type 5 events

1. Nov 17

   PIPE financing & POC

   24h Move

   +2.7%

   PIPE financing to fund SIM0505 and LNCB74 proof-of-concept readouts.

2. Oct 16

   SIM0505 trial expansion

   24h Move

   +27.8%

   Expansion of SIM0505 Phase 1 into U.S. with encouraging mid-dose responses.

3. Jul 24

   NC605 preclinical data

   24h Move

   +17.3%

   Preclinical NC605 data showing improved bone outcomes in OI mouse models.

4. Jan 10

   LNCB74 first patient

   24h Move

   -6.1%

   First patient dosed in Phase 1 LNCB74 study across multiple cancers.

5. Dec 10

   LNCB74 IND accepted

   24h Move

   -2.6%

   FDA acceptance of IND enabling Phase 1 trial initiation for LNCB74.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fast track designation, antibody drug conjugate, adc, topoisomerase 1 inhibitor, +2 more

6 terms

fast track designation regulatory

"The U.S. Food and Drug Administration (FDA) has granted Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

antibody drug conjugate medical

"SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody"

An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.

adc medical

"SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

topoisomerase 1 inhibitor medical

"and a proprietary topoisomerase 1 inhibitor (TOPOi) payload."

A topoisomerase 1 inhibitor is a type of cancer drug that blocks an enzyme whose job is to untwist and relieve tension in DNA during copying; by preventing that untangling, the drug causes DNA damage in rapidly dividing cells and can trigger cancer cell death. For investors, these drugs matter because their success in clinical trials, regulatory approvals, patent position, or commercial uptake can drive a biotech or pharma company’s value and future revenue like a new product launch would for any business.

platinum resistant ovarian cancer medical

"for the treatment of women with platinum resistant ovarian cancer (PROC)"

A form of ovarian cancer that stops responding to standard platinum-based chemotherapy, usually defined when the disease returns or worsens within about six months after treatment. Think of it like a weed that no longer dies from a common herbicide: treatments that once worked are much less effective, which matters to investors because it creates a clear unmet medical need, influences drug development strategy, trial design, and market opportunity for new therapies.

cdh6 medical

"targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor"

CDH6 is a gene that makes cadherin-6, a protein on cell surfaces that helps cells stick together and communicate during development and tissue maintenance. Investors pay attention because changes in CDH6 levels or function can signal disease, serve as a biomarker, or be a drug target—think of it like a Velcro patch whose condition can indicate a product problem or an opportunity for a fix that creates commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) 
• Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026

BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

“Securing Fast Track designation for SIM0505 validates the urgent, unmet need for new treatments for platinum resistant ovarian cancer and enables us to work more closely with FDA to accelerate development. We believe this designation will help to streamline and de-risk development through proactive and ongoing engagement with FDA,” said Michael Richman, President and CEO of NextCure. “We are committed to bringing SIM0505 to patients as quickly as possible and we plan to initiate dose optimization in ovarian cancer patients in the second quarter of 2026. In addition, we look forward to presenting Phase 1 data on the program at the upcoming 2026 American Society of Clinical Oncology conference.”

About Fast Track Designation

Fast Track Designation is an FDA process designed to facilitate the development of new therapies to treat serious conditions and fulfill an unmet medical need. Drug candidates that receive Fast Track Designation are eligible for more frequent meetings and written interactions with the FDA, rolling review and priority review.

About SIM0505

SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.

Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries

Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com

Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does FDA Fast Track designation mean for NextCure's SIM0505 (NXTC)?

It speeds development and review through more frequent FDA interactions and potential rolling submissions. According to NextCure, Fast Track will enable closer, proactive engagement with FDA to streamline and de-risk SIM0505 development for platinum-resistant ovarian cancer.

When will NextCure (NXTC) begin dose optimization for SIM0505 in ovarian cancer?

Dose optimization is planned to begin in the second quarter of 2026. According to NextCure, the company expects to start ovarian cancer dose optimization in Q2 2026 to refine dosing for subsequent studies.

Will NextCure present SIM0505 clinical data at ASCO 2026 for NXTC shareholders?

Yes, NextCure plans to present Phase 1 data at the 2026 American Society of Clinical Oncology conference. According to NextCure, Phase 1 results will be shared at ASCO 2026, providing initial clinical readouts to investors.

What is SIM0505 and how does it work for ovarian cancer (NXTC)?

SIM0505 is an investigational antibody-drug conjugate targeting Cadherin-6 with a topoisomerase 1 inhibitor payload. According to NextCure, the ADC combines a CDH6-targeting antibody with a proprietary TOPOi payload to selectively deliver cytotoxic activity.

How might Fast Track designation affect NextCure's (NXTC) regulatory timeline?

Fast Track can shorten development and review timelines via rolling submissions and enhanced FDA communications. According to NextCure, the designation aims to accelerate SIM0505 development through ongoing, proactive engagement with FDA.